Xtant Medical Announces First Quarter 2022 Financial Results

Press Releases

View printer-friendly version

Xtant Medical Announces First Quarter 2022 Financial Results


BELGRADE, Mont., May 05, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2022.

“By building momentum in our business, underscored by first quarter revenue growth and the progress of our key strategic growth pillars, we are pleased with the promising start to 2022,” said Sean Browne, President & CEO of Xtant Medical. “First quarter revenue increased by 3% and we achieved an impressive 13% year-over-year growth in our biologics business. Our top-line was driven by our 2021 initiatives, including multiple successful product launches, expansion of our distribution network and entry into adjacent markets. With our strategic plan firmly in place and guided by our mission, we look forward to continue bringing our leading spine brand to patients in need.”

First Quarter 2022 Financial Results

First quarter 2022 revenue was $13.0 million, compared to $12.5 million for the same period in 2021. The increase in revenue is attributed primarily to introductions of new products and greater private label and original equipment manufacturer (OEM) orthobiologics sales.

Gross margin for the first quarter of 2022 was 58.3%, compared to 64.5% for the same period in 2021. The decrease was primarily attributable to the sell-through of product subject to higher production costs, a shift in product sales mix with a proportional increase in private label and OEM channel sales and greater inventory reserve expense.

Operating expenses for the first quarter of 2022 totaled $9.4 million, compared to $8.1 million for the first quarter of 2021. The increase was primarily due to increased expense related to licenses and fees, additional bad debt expense, costs related to the enterprise resource planning system upgrades, additional sales commissions and greater salaries and wage expenses.

First quarter 2022 net loss totaled $2.2 million, or $0.03 per share, compared to the first quarter 2021 net loss of $29,000, or $0.00 per share.

Non-GAAP Adjusted EBITDA for the first quarter of 2022 totaled a loss of $0.9 million, compared to Non-GAAP Adjusted EBITDA of $0.8 million for the same period in 2021. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, separation related expenses and legal settlement reserves. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.

Conference Call

Xtant Medical will host a webcast and conference call to discuss the first quarter 2022 financial results on Thursday, May 5, 2022 at 9:00 AM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com, under “Investor Info.”

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” ‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going forward,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s continued investment in and the future success of its key growth initiatives and their impact on the Company’s future growth strategy, operating results and financial performance. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results and financial performance; the ability to increase or maintain revenue; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory if revenues continue to decrease; the ability to remain competitive; the ability to innovate, develop and introduce new products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company’s dependence on key independent agents for a significant portion of its revenue; the effect of the COVID-19 pandemic and hospital staffing shortages on the Company’s business, operating results and financial condition, especially when they affect key markets; the Company’s ability to implement successfully its future growth initiatives and risks associated therewith; the effect of product sales mix changes on the Company’s financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 8, 2022 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 anticipated to be filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact

David Carey
Lazar FINN
Ph: 212-867-1762
Email: david.carey@finnpartners.com 

(In thousands, except number of shares and par value)
    March 31, 2022   December 31, 2021
Current Assets:        
Cash and cash equivalents   $ 16,971     $ 18,387  
Trade accounts receivable, net of allowance for credit losses and
doubtful accounts of $554 and $653, respectively
    7,545       7,154  
Inventories     17,300       17,945  
Prepaid and other current assets     944       844  
    Total current assets     42,760       44,330  
Property and equipment, net     5,409       5,212  
Right-of -use asset, net     1,146       1,258  
Goodwill     3,205       3,205  
Intangible assets, net     386       400  
Other assets     264       287  
    Total Assets   $ 53,170     $ 54,692  
Current Liabilities:        
Accounts payable   $ 2,774     $ 2,615  
Accrued liabilities     4,345       4,349  
Current portion of lease liability     471       462  
Current portion of finance lease obligations     31       31  
Line of credit     3,607       3,620  
    Total current liabilities     11,228       11,077  
Long-term Liabilities:        
Lease liability, less current portion     720       842  
Finance lease obligation, less current portion     95       103  
Long-term debt, plus premium and less issuance cost     11,844       11,787  
    Total Liabilities     23,887       23,809  
Stockholders' Equity        
Preferred stock     -       -  
Common stock     -       -  
Additional paid-in capital     266,681       266,068  
Accumulated deficit     (237,398 )     (235,185 )
    Total Stockholders’ Equity     29,283       30,883  
    Total Liabilities & Stockholders’ Equity   $ 53,170     $ 54,692  

(Unaudited, in thousands, except number of shares and per share amounts)
    Three Months Ended March 31,
    2022   2021
Orthopedic product sales   $ 12,950   $ 12,509
Other revenue   9   33
Total revenue   12,959   12,542
Cost of sales   5,399   4,451
Gross profit   7,560   8,091
Gross profit %   58.3%   64.5%
Operating expenses        
General and administrative   3,969   3,027
Sales and marketing   5,209   4,855
Research and development   213   214
    9,391   8,096
Loss from operations   (1,831)   (5)
Other income        
Interest expense   (359)   (1)
Total Other Expense   (359)   (1)
     Net Loss from Operations Before Provision for Income Taxes   (2,190)   (6)
Provision for income taxes        
Current and deferred   (23)   (23)
Net Loss   $ (2,213)   $ (29)
Net loss per share:        
Basic   $ (0.03)   $ (0.00)
Dilutive   $ (0.03)   $ (0.00)
Shares used in the computation:        
Basic   87,191,341   81,248,875
Dilutive   87,191,341   81,248,875

(Unaudited, in thousands)
    Three Months Ended March 31,
      2022       2021  
Operating activities:        
Net loss   $ (2,213 )   $ (29 )
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization     281       375  
Gain on disposal of fixed assets     (73 )     (32 )
Non-cash interest     58       -  
Non-cash rent     -       3  
Stock-based compensation     613       456  
Provision for reserve on accounts receivable     191       (63 )
Provision for excess and obsolete inventory     318       150  
Changes in operating assets and liabilities:        
Accounts receivable     (582 )     (83 )
Inventories     327       (383 )
Prepaid and other assets     (78 )     (349 )
Accounts payable     159       (459 )
Accrued liabilities     (5 )     (893 )
   Net cash used in operating activities     (1,004 )     (1,307 )
Investing activities:        
Purchases of property and equipment     (484 )     (542 )
Proceeds from sale of fixed assets     93       59  
   Net cash used in investing activities     (391 )     (483 )
Financing activities:        
Payments on financing leases     (8 )     (25 )
Payments on long-term debt     -       (308 )
Borrowings on line of credit     12,316       -  
Repayments on line of credit     (12,329 )     -  
Proceeds from private place, net of cash issuance costs     -       18,425  
   Net cash (used in) provided by financing activities     (21 )     18,092  
Net change in cash and cash equivalents     (1,416 )     16,302  
Cash and cash equivalents at beginning of period     18,387       2,341  
Cash and cash equivalents at end of period   $ 16,971     $ 18,643  

(Unaudited, in thousands)
    Three Months Ended March 31,
    2022   2021
Net Loss   $ (2,213)   $ (29)
Depreciation and amortization   281   375
Interest expense   359   1
Tax expense   23   23
  Non-GAAP EBITDA   (1,550)   370
  Non-GAAP EBITDA/Total revenue   -12.0%   3.0%
Stock-based compensation   614   456
Separation-related expenses   3   -
  Non-GAAP Adjusted EBITDA   $ (933)   $ 826
  Non-GAAP Adjusted EBITDA/Total revenue   -7.2%   6.6%

Primary Logo

Source: Xtant Medical, Inc.